Hub : Traits :

Worrier / anxious feelings

744 significantly associated models · 126 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	3	49598064	51234774	7	2	1.8e-10	5.2e-08	0.582	99	CYB561D2 SEMA3B-AS1
2	3	51616334	54077726	13	1	1.2e-13	1.3e-11	0.115	95	ITIH4-AS1
3	3	84317575	86808226	1	1	2.4e-16	3.6e-16	1.000	100	CADM2
4	3	135173458	137261517	5	1	2.0e-11	1.6e-10	1.000	100	STAG1
5	4	118707160	119423789	1	1	2.1e-07	6.9e-07	0.030	81	NDST3
6	5	101762909	103244640	1	1	1.5e-07	2.1e-08	0.050	88	PPIP5K2
7	7	126529931	128425768	3	2	4.8e-09	2.3e-10	0.011	84	LRRC4 SND1
8	8	8092025	13120332	40	1	5.9e-28	4.2e-24	0.323	99	AF131215.2
9	10	103527782	105647095	12	1	2.5e-13	1.1e-11	0.806	100	AS3MT
10	11	56666189	58178587	4	1	7.7e-09	5.8e-08	0.891	100	ZDHHC5
11	11	94825532	96261289	2	1	1.6e-08	6.3e-08	0.217	95	AP001877.1
12	11	130498156	131034037	1	1	1.5e-07	3.7e-06	0.736	100	SNX19
13	11	133079948	134525648	1	1	9.2e-09	3.0e-08	0.079	90	IGSF9B
14	12	109231851	110605559	1	1	8.1e-08	1.7e-07	0.205	94	KCTD10
15	14	74424938	76210831	5	2	2.7e-11	3.0e-10	0.999	100	AREL1 MLH3
16	16	29580611	31758245	7	2	3.9e-08	4.2e-08	0.601	99	MYST1 YPEL3
17	17	42607368	45796313	18	1	5.4e-09	3.1e-08	0.863	100	MAPT
18	18	52209411	54028036	1	1	1.5e-09	2.3e-10	0.017	86	TCF4
19	22	40472399	41895409	1	1	1.1e-07	8.1e-08	0.199	94	SLC25A17

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder or Schizophrenia	4.64	5	4	8.9	1.00	1.8e-04	AS3MT IGSF9B ITIH4-AS1 NDST3 SLC25A17
Depressed Affect (Nagel 2018)	6.50	8	2	4.4	0.95	2.5e-04	AREL1 KCTD10 MAPT MLH3 MYST1 STAG1 TCF4 ZDHHC5
Depression (Nagel 2018)	5.67	4	2	4.4	1.00	6.9e-04	CYB561D2 MAPT STAG1 ZDHHC5
Intelligence (Savage-Jansen 2018)	4.32	8	4	8.9	-0.98	2.7e-05	AP001877.1 ITIH4-AS1 LRRC4 MAPT PPIP5K2 SND1 STAG1 ZDHHC5
Neuroticism (Nagel 2018)	12.69	15	12	26.7	0.95	3.5e-08	AREL1 AS3MT CYB561D2 IGSF9B ITIH4-AS1 KCTD10 MAPT MLH3 MYST1 NDST3 SLC25A17 SNX19 STAG1 TCF4 ZDHHC5
Schizophrenia (2018)	5.39	6	3	6.7	0.98	7.0e-04	AS3MT IGSF9B ITIH4-AS1 SLC25A17 STAG1 ZDHHC5
Worry (Nagel 2018)	15.87	19	14	31.1	0.99	2.5e-15	AP001877.1 AREL1 AS3MT CADM2 CYB561D2 IGSF9B ITIH4-AS1 KCTD10 MAPT MLH3 MYST1 NDST3 PPIP5K2 SEMA3B-AS1 SLC25A17 SNX19 STAG1 YPEL3 ZDHHC5
Alzheimer’s Disease (including proxy)	2.22	2	0	0.0	0.00	1.0e+00	MYST1 YPEL3
Major Depression (MDD)	4.10	2	0	0.0	0.00	1.0e+00	TCF4 ZDHHC5
Verbal and Numeric Reasoning (VNR)	4.23	4	2	4.4	-0.99	1.2e-02	ITIH4-AS1 MAPT PPIP5K2 SND1
Breast Cancer	1.65	1	1	2.2	0.00	1.0e+00	MAPT
Ovarian Cancer	2.27	1	1	2.2	0.00	1.0e+00	MAPT
Coronary Artery Disease (CAD)	2.27	1	0	0.0	0.00	1.0e+00	AS3MT
HDL Cholesterol	1.74	1	1	2.2	0.00	1.0e+00	KCTD10
Lupus	1.63	1	0	0.0	0.00	1.0e+00	AF131215.2
Neuroticism (2016)	8.39	5	2	4.4	0.99	1.1e-03	AF131215.2 AREL1 MAPT SLC25A17 TCF4
Rheumatoid Arthritis	1.94	1	0	0.0	0.00	1.0e+00	PPIP5K2
Schizophrenia (2014)	5.87	7	3	6.7	0.98	1.3e-04	AS3MT IGSF9B ITIH4-AS1 SLC25A17 SNX19 STAG1 ZDHHC5
Triglycerides	1.52	1	0	0.0	0.00	1.0e+00	MYST1
Blood Eosinophil Count	2.23	5	5	11.1	0.22	7.2e-01	ITIH4-AS1 KCTD10 MAPT SLC25A17 YPEL3
Blood Platelet Count	1.32	8	5	11.1	-0.45	2.7e-01	AREL1 AS3MT CYB561D2 ITIH4-AS1 SND1 STAG1 YPEL3 ZDHHC5
Blood Red Count	3.40	9	5	11.1	0.70	3.6e-02	AP001877.1 AS3MT CYB561D2 ITIH4-AS1 MAPT MYST1 PPIP5K2 YPEL3 ZDHHC5
Blood White Count	0.81	3	1	2.2	0.00	1.0e+00	KCTD10 MAPT PPIP5K2
Heel T-Score	1.72	6	1	2.2	0.28	5.8e-01	AREL1 MAPT MLH3 MYST1 SLC25A17 ZDHHC5
BMI	3.14	6	6	13.3	-0.99	1.4e-04	AS3MT CADM2 ITIH4-AS1 MYST1 SNX19 YPEL3
Height	1.86	12	9	20.0	-0.06	8.6e-01	AP001877.1 AREL1 AS3MT CYB561D2 ITIH4-AS1 MAPT NDST3 PPIP5K2 SEMA3B-AS1 STAG1 TCF4 YPEL3
Waist Hip Ratio (WHR)	2.97	5	5	11.1	0.65	2.3e-01	CYB561D2 ITIH4-AS1 MAPT PPIP5K2 STAG1
Systolic Blood Pressure	3.67	7	6	13.3	0.25	5.8e-01	AREL1 AS3MT CADM2 MAPT SND1 YPEL3 ZDHHC5
Smoking Status	4.77	3	2	4.4	0.00	1.0e+00	AS3MT CADM2 ITIH4-AS1
Allergy or Eczema	1.22	1	1	2.2	0.00	1.0e+00	SLC25A17
Cardiovascular Disease	1.92	2	1	2.2	0.00	1.0e+00	AS3MT MYST1
Hypothyroidism (self reported)	1.97	1	1	2.2	0.00	1.0e+00	PPIP5K2
Type 2 Diabetes (T2D) (2018)	2.03	1	0	0.0	0.00	1.0e+00	PPIP5K2
Lung FEV1/FVC ratio	1.47	3	1	2.2	0.00	1.0e+00	AREL1 MAPT ZDHHC5
Lung FVC	3.54	4	4	8.9	-0.49	5.1e-01	MAPT MYST1 SEMA3B-AS1 TCF4
Neuroticism	12.07	15	11	24.4	0.95	5.7e-08	AREL1 AS3MT CADM2 CYB561D2 IGSF9B KCTD10 MAPT MLH3 MYST1 NDST3 SEMA3B-AS1 SLC25A17 STAG1 TCF4 ZDHHC5
Chronotype (morning person)	1.88	1	1	2.2	0.00	1.0e+00	CYB561D2
Hair Pigment	0.14	1	1	2.2	0.00	1.0e+00	SLC25A17
Tanning	0.79	3	1	2.2	0.00	1.0e+00	AREL1 CADM2 ITIH4-AS1
Hand grip strength (left)	5.50	9	4	8.9	-0.19	6.3e-01	AREL1 AS3MT CADM2 IGSF9B ITIH4-AS1 LRRC4 MAPT TCF4 YPEL3
Number of treatments/medications taken	3.20	1	1	2.2	0.00	1.0e+00	AREL1
Sensitivity / hurt feelings	8.71	7	2	4.4	0.84	1.7e-02	AF131215.2 IGSF9B KCTD10 MAPT NDST3 STAG1 ZDHHC5
Frequency of depressed mood in last 2 weeks	6.05	4	0	0.0	1.00	1.7e-03	CYB561D2 MAPT STAG1 ZDHHC5
Hearing difficulty/problems: Yes	1.82	1	0	0.0	0.00	1.0e+00	MAPT
Relative age of first facial hair	3.05	1	1	2.2	0.00	1.0e+00	MAPT
Systolic blood pressure, automated reading	3.82	5	3	6.7	-0.40	5.1e-01	AF131215.2 AREL1 AS3MT MAPT ZDHHC5
Impedance of leg (right)	4.77	12	9	20.0	0.77	3.3e-03	AF131215.2 AP001877.1 AREL1 AS3MT CADM2 CYB561D2 ITIH4-AS1 LRRC4 MAPT MLH3 SEMA3B-AS1 YPEL3
Leg fat-free mass (left)	2.86	5	4	8.9	-0.89	4.5e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3
Trunk fat percentage	3.04	6	4	8.9	-0.43	3.9e-01	AREL1 MAPT MYST1 SLC25A17 SNX19 ZDHHC5
Hand grip strength (right)	3.94	5	1	2.2	0.16	7.9e-01	CADM2 MAPT NDST3 TCF4 YPEL3
Current tobacco smoking	2.60	2	0	0.0	0.00	1.0e+00	AS3MT SLC25A17
Maternal smoking around birth	2.14	1	0	0.0	0.00	1.0e+00	AS3MT
Fed-up feelings	5.76	5	4	8.9	0.96	9.9e-03	AF131215.2 AREL1 MAPT STAG1 ZDHHC5
Frequency of unenthusiasm / disinterest in last 2 weeks	4.71	2	0	0.0	0.00	1.0e+00	STAG1 ZDHHC5
Relative age voice broke	2.32	1	1	2.2	0.00	1.0e+00	MAPT
Taking other prescription medications	3.31	1	1	2.2	0.00	1.0e+00	AREL1
Age when periods started (menarche)	1.37	1	0	0.0	0.00	1.0e+00	MAPT
Heel bone mineral density (BMD) T-score, automated (left)	3.17	2	1	2.2	0.00	1.0e+00	AF131215.2 MAPT
High blood pressure	2.52	3	1	2.2	0.00	1.0e+00	AF131215.2 MAPT MYST1
Sitting height	1.58	4	4	8.9	-0.46	5.4e-01	ITIH4-AS1 MAPT YPEL3 ZDHHC5
Body mass index (BMI)	3.73	7	7	15.6	-0.97	2.5e-04	AF131215.2 AS3MT CADM2 ITIH4-AS1 MYST1 SNX19 YPEL3
Impedance of leg (left)	4.61	12	9	20.0	0.77	3.3e-03	AF131215.2 AP001877.1 AREL1 AS3MT CADM2 CYB561D2 ITIH4-AS1 LRRC4 MAPT MLH3 SEMA3B-AS1 YPEL3
Leg predicted mass (left)	2.85	5	4	8.9	-0.89	4.6e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3
Trunk fat mass	2.90	6	4	8.9	-0.94	4.5e-03	AS3MT CADM2 MAPT MYST1 SNX19 YPEL3
Waist circumference	2.78	5	3	6.7	-0.96	9.0e-03	AS3MT CADM2 MYST1 SNX19 YPEL3
Number of incorrect matches in round	4.01	3	0	0.0	0.00	1.0e+00	AS3MT MYST1 NDST3
Past tobacco smoking	4.48	3	2	4.4	0.00	1.0e+00	AS3MT CADM2 ITIH4-AS1
Alcohol usually taken with meals	2.01	1	0	0.0	0.00	1.0e+00	ZDHHC5
Nervous feelings	13.03	13	9	20.0	0.99	1.1e-10	AF131215.2 AREL1 AS3MT CADM2 CYB561D2 ITIH4-AS1 MAPT MYST1 SEMA3B-AS1 SLC25A17 SNX19 STAG1 YPEL3
Frequency of tenseness / restlessness in last 2 weeks	6.02	3	2	4.4	0.00	1.0e+00	KCTD10 MAPT STAG1
Hearing difficulty/problems with background noise	2.38	1	1	2.2	0.00	1.0e+00	MAPT
Hair/balding pattern: Pattern 2	1.75	1	0	0.0	0.00	1.0e+00	MAPT
Had menopause	1.84	1	0	0.0	0.00	1.0e+00	SEMA3B-AS1
Forced vital capacity (FVC)	2.99	4	2	4.4	0.34	6.6e-01	ITIH4-AS1 MAPT MYST1 NDST3
Heel bone mineral density (BMD) T-score, automated (right)	3.21	2	1	2.2	0.00	1.0e+00	AF131215.2 MAPT
Ever unenthusiastic/disinterested for a whole week	3.30	1	0	0.0	0.00	1.0e+00	MAPT
Qualifications: None of the above	2.82	1	1	2.2	0.00	1.0e+00	AP001877.1
Mouth/teeth dental problems	2.23	2	0	0.0	0.00	1.0e+00	KCTD10 MAPT
Fluid intelligence score	3.22	3	0	0.0	0.00	1.0e+00	MAPT PPIP5K2 STAG1
Illnesses of siblings	1.70	1	0	0.0	0.00	1.0e+00	MYST1
Neuroticism score	13.59	15	9	20.0	0.98	3.6e-10	AF131215.2 AREL1 CYB561D2 IGSF9B KCTD10 MAPT MLH3 MYST1 NDST3 SEMA3B-AS1 SLC25A17 SNX19 STAG1 TCF4 ZDHHC5
Weight	3.08	6	6	13.3	-0.90	1.3e-02	AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Impedance of arm (right)	4.53	9	5	11.1	0.72	2.8e-02	AF131215.2 CADM2 CYB561D2 ITIH4-AS1 MAPT MLH3 SEMA3B-AS1 YPEL3 ZDHHC5
Arm fat percentage (right)	3.18	7	4	8.9	-0.68	9.5e-02	AF131215.2 AS3MT ITIH4-AS1 MYST1 SNX19 YPEL3 ZDHHC5
Trunk fat-free mass	2.59	5	3	6.7	-0.81	9.9e-02	AF131215.2 AS3MT CADM2 MLH3 YPEL3
Hip circumference	3.22	6	4	8.9	-0.88	2.0e-02	AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Frequency of tiredness / lethargy in last 2 weeks	4.09	3	1	2.2	0.00	1.0e+00	KCTD10 STAG1 ZDHHC5
Falls in the last year	2.85	1	1	2.2	0.00	1.0e+00	SEMA3B-AS1
Hair/balding pattern: Pattern 3	3.40	1	1	2.2	0.00	1.0e+00	MAPT
Number of live births	2.42	2	1	2.2	0.00	1.0e+00	CADM2 MAPT
Forced expiratory volume in 1-second (FEV1)	3.53	4	2	4.4	0.44	5.6e-01	AF131215.2 MAPT MYST1 NDST3
Noisy workplace	1.36	1	0	0.0	0.00	1.0e+00	MAPT
Qualifications: A levels/AS levels or equivalent	3.09	3	1	2.2	0.00	1.0e+00	AP001877.1 MAPT NDST3
Serious illness, injury or assault of a close relative in last 2 years	2.39	1	0	0.0	0.00	1.0e+00	SND1
Mouth/teeth dental problems: Dentures	2.36	2	0	0.0	0.00	1.0e+00	AF131215.2 STAG1
Medication: Ibuprofen (e.g. Nurofen)	1.54	1	0	0.0	0.00	1.0e+00	MAPT
Forced expiratory volume in 1-second (FEV1), Best measure	3.16	2	2	4.4	0.00	1.0e+00	MAPT MYST1
Impedance of arm (left)	4.47	9	5	11.1	0.72	2.9e-02	AF131215.2 AS3MT CADM2 CYB561D2 ITIH4-AS1 MAPT SEMA3B-AS1 YPEL3 ZDHHC5
Arm fat mass (right)	3.30	6	5	11.1	-0.93	7.1e-03	AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Trunk predicted mass	2.60	5	3	6.7	-0.81	9.9e-02	AF131215.2 AS3MT CADM2 MLH3 YPEL3
Standing height	1.78	8	5	11.1	0.11	7.9e-01	AF131215.2 AS3MT ITIH4-AS1 MAPT PPIP5K2 SEMA3B-AS1 STAG1 YPEL3
Tense / 'highly strung'	8.41	9	2	4.4	0.98	4.7e-06	AF131215.2 AREL1 CADM2 CYB561D2 MAPT MYST1 SEMA3B-AS1 SLC25A17 STAG1
Seen doctor (GP) for nerves, anxiety, tension or depression	4.93	3	1	2.2	0.00	1.0e+00	AREL1 IGSF9B TCF4
Hair/balding pattern: Pattern 4	4.98	1	1	2.2	0.00	1.0e+00	MAPT
Birth weight of first child	2.22	2	0	0.0	0.00	1.0e+00	AS3MT SND1
Peak expiratory flow (PEF)	3.24	3	1	2.2	0.00	1.0e+00	AF131215.2 MAPT NDST3
Qualifications: O levels/GCSEs or equivalent	2.26	1	0	0.0	0.00	1.0e+00	AP001877.1
Medication: Paracetamol	4.22	1	1	2.2	0.00	1.0e+00	MAPT
Headache pain in last month	4.32	3	1	2.2	0.00	1.0e+00	ITIH4-AS1 MAPT ZDHHC5
Hypothyroidism/myxoedema (self-reported)	1.98	1	0	0.0	0.00	1.0e+00	PPIP5K2
Birth weight	2.04	3	0	0.0	0.00	1.0e+00	AS3MT LRRC4 SND1
Chronic bronchitis/emphysema (mother)	2.37	1	0	0.0	0.00	1.0e+00	MLH3
High blood pressure (siblings)	2.06	1	0	0.0	0.00	1.0e+00	MYST1
Forced vital capacity (FVC), Best measure	2.78	3	2	4.4	0.00	1.0e+00	ITIH4-AS1 MAPT MYST1
Body fat percentage	3.08	5	3	6.7	0.01	9.9e-01	AREL1 MYST1 NDST3 SNX19 ZDHHC5
Leg fat percentage (right)	3.06	6	3	6.7	-0.27	6.0e-01	AF131215.2 AREL1 CADM2 MYST1 NDST3 SNX19
Arm fat-free mass (right)	2.85	5	5	11.1	-0.86	6.1e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3
Comparative body size at age 10	3.19	4	3	6.7	-0.37	6.3e-01	AF131215.2 CADM2 CYB561D2 MYST1
Worry too long after embarrassment	6.69	5	3	6.7	0.98	4.4e-03	AF131215.2 KCTD10 MAPT STAG1 ZDHHC5
Number of children fathered	2.57	1	1	2.2	0.00	1.0e+00	CADM2
Age at first live birth	2.22	2	0	0.0	0.00	1.0e+00	AF131215.2 AP001877.1
Qualifications: College or University degree	3.38	6	3	6.7	-0.54	2.7e-01	AP001877.1 CADM2 MAPT PPIP5K2 SND1 ZDHHC5
Medication for pain relief, constipation, heartburn	3.45	3	1	2.2	0.00	1.0e+00	AREL1 MAPT NDST3
Whole body fat mass	3.07	6	5	11.1	-0.91	1.3e-02	AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Leg fat mass (right)	3.35	6	6	13.3	-0.94	5.9e-03	AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Arm predicted mass (right)	2.87	5	5	11.1	-0.86	6.0e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3
Pulse rate, automated reading	2.00	2	0	0.0	0.00	1.0e+00	CYB561D2 ZDHHC5
Alcohol intake frequency.	4.14	6	3	6.7	0.58	2.3e-01	CADM2 LRRC4 MAPT TCF4 YPEL3 ZDHHC5
Comparative height size at age 10	1.89	5	5	11.1	0.55	3.3e-01	ITIH4-AS1 MAPT STAG1 TCF4 YPEL3
Number of full sisters	2.36	1	1	2.2	0.00	1.0e+00	CADM2
Suffer from 'nerves'	7.63	6	2	4.4	0.99	5.6e-05	AF131215.2 AREL1 AS3MT CADM2 MAPT MYST1
Overall health rating	2.86	1	0	0.0	0.00	1.0e+00	MYST1
Age at last live birth	2.61	2	0	0.0	0.00	1.0e+00	AF131215.2 AP001877.1
Hypertension (Self-reported)	2.49	3	1	2.2	0.00	1.0e+00	AF131215.2 MAPT MYST1
Smoking status: Previous	3.91	1	1	2.2	0.00	1.0e+00	CADM2
Whole body fat-free mass	2.76	5	4	8.9	-0.84	7.3e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3
Leg fat-free mass (right)	2.92	5	4	8.9	-0.88	5.0e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3
Arm fat percentage (left)	3.05	6	3	6.7	-0.68	1.3e-01	AF131215.2 AS3MT MYST1 SNX19 YPEL3 ZDHHC5
Average weekly red wine intake	2.98	2	0	0.0	0.00	1.0e+00	AP001877.1 ZDHHC5
Handedness (chirality/laterality): Left-handed	3.03	2	1	2.2	0.00	1.0e+00	LRRC4 MAPT
Mood swings	7.97	5	4	8.9	0.91	3.0e-02	AF131215.2 AREL1 MAPT SLC25A17 TCF4
Loneliness, isolation	3.06	1	0	0.0	0.00	1.0e+00	MAPT
Friendships satisfaction	2.43	1	0	0.0	0.00	1.0e+00	AP001877.1
Qualifications: nursing, teaching	2.19	1	0	0.0	0.00	1.0e+00	CADM2
Mouth/teeth dental problems: Mouth ulcers	3.67	2	1	2.2	0.00	1.0e+00	AP001877.1 MAPT
Medication for cholesterol	2.75	2	0	0.0	0.00	1.0e+00	MAPT MYST1
Smoking status: Current	2.67	1	0	0.0	0.00	1.0e+00	AS3MT
Forced expiratory volume in 1-second (FEV1), predicted percentage	3.56	3	2	4.4	0.00	1.0e+00	AF131215.2 MAPT MYST1
Whole body water mass	2.76	5	4	8.9	-0.84	7.2e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3
Leg predicted mass (right)	2.92	5	4	8.9	-0.88	5.2e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3
Arm fat mass (left)	3.29	6	6	13.3	-0.93	7.3e-03	AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Number of self-reported non-cancer illnesses	2.15	1	0	0.0	0.00	1.0e+00	AREL1
Average weekly champagne plus white wine intake	1.64	1	0	0.0	0.00	1.0e+00	MAPT
Miserableness	5.37	5	3	6.7	0.64	2.5e-01	AF131215.2 MAPT NDST3 STAG1 TCF4
Guilty feelings	6.29	4	3	6.7	0.98	1.7e-02	AF131215.2 AREL1 MAPT ZDHHC5
Wears glasses or contact lenses	1.69	1	0	0.0	0.00	1.0e+00	CADM2
Medication: Blood pressure	2.90	2	2	4.4	0.00	1.0e+00	AF131215.2 MAPT
High cholesterol (Self-reported)	1.97	1	0	0.0	0.00	1.0e+00	MYST1
Medication: Bendroflumethiazide	2.47	1	0	0.0	0.00	1.0e+00	AF131215.2
Medication: Paracetamol	3.87	1	1	2.2	0.00	1.0e+00	MAPT
Alcohol drinker status: Never	1.84	1	0	0.0	0.00	1.0e+00	CADM2
Ever smoked	3.68	2	1	2.2	0.00	1.0e+00	AS3MT CADM2
Basal metabolic rate	2.83	5	5	11.1	-0.85	6.6e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3
Leg fat percentage (left)	3.01	7	2	4.4	-0.29	5.2e-01	AF131215.2 AREL1 CADM2 ITIH4-AS1 MYST1 NDST3 SNX19
Arm fat-free mass (left)	2.92	5	5	11.1	-0.86	6.4e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3
Irritability	6.02	6	3	6.7	0.98	5.6e-04	AF131215.2 AREL1 MAPT MYST1 SLC25A17 TCF4
Risk taking	5.73	4	1	2.2	-0.91	8.8e-02	AF131215.2 CADM2 LRRC4 SND1
Fractured/broken bones in last 5 years	2.38	1	0	0.0	0.00	1.0e+00	SEMA3B-AS1
Diastolic blood pressure, automated reading	1.94	2	1	2.2	0.00	1.0e+00	AF131215.2 MYST1
Ever depressed for a whole week	2.53	1	0	0.0	0.00	1.0e+00	MAPT
Vascular/heart problems diagnosed by doctor	2.35	2	1	2.2	0.00	1.0e+00	AF131215.2 MYST1
Pain experienced in last month	2.92	2	0	0.0	0.00	1.0e+00	KCTD10 MAPT
Impedance of whole body	4.98	11	8	17.8	0.70	1.6e-02	AF131215.2 AREL1 AS3MT CADM2 CYB561D2 ITIH4-AS1 LRRC4 MAPT MLH3 SEMA3B-AS1 YPEL3
Leg fat mass (left)	3.30	6	6	13.3	-0.93	6.4e-03	AF131215.2 AS3MT CADM2 MYST1 SNX19 YPEL3
Arm predicted mass (left)	2.95	5	5	11.1	-0.87	5.7e-02	AF131215.2 AS3MT CADM2 MYST1 YPEL3

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	20	0.57	1.9
GTEx	Adipose Visceral Omentum	11	0.54	2.0
GTEx	Adrenal Gland	10	0.69	2.1
GTEx	Artery Aorta	19	0.64	2.0
GTEx	Artery Coronary	10	0.85	2.1
GTEx	Artery Tibial	14	0.37	1.9
GTEx	Brain Caudate basal ganglia	7	0.76	2.0
GTEx	Brain Cerebellar Hemisphere	9	0.60	2.0
GTEx	Brain Cerebellum	11	0.55	1.9
GTEx	Brain Cortex	8	0.77	2.2
GTEx	Brain Frontal Cortex BA9	7	0.76	2.2
GTEx	Brain Hippocampus	5	0.95	2.1
GTEx	Brain Hypothalamus	5	0.85	2.1
GTEx	Brain Nucleus accumbens basal ganglia	7	0.81	2.0
GTEx	Brain Putamen basal ganglia	6	0.96	2.1
GTEx	Breast Mammary Tissue	14	0.71	2.0
GTEx	Breast Mammary Tissue (Male)	10	0.84	2.0
GTEx	Breast Mammary Tissue (Female)	9	0.55	1.9
GTEx	Cells EBV-transformed lymphocytes	15	1.05	2.1
GTEx	Cells Transformed fibroblasts	14	0.33	1.8
GTEx	Colon Sigmoid	13	0.89	2.1
GTEx	Colon Transverse	15	0.73	2.1
GTEx	Esophagus Gastroesophageal Junction	10	0.69	2.1
GTEx	Esophagus Mucosa	16	0.48	1.9
GTEx	Esophagus Muscularis	15	0.46	2.0
GTEx	Heart Atrial Appendage	11	0.70	2.0
GTEx	Heart Left Ventricle	11	0.72	2.1
GTEx	Liver	7	0.98	2.1
GTEx	Lung	20	0.70	1.9
GTEx	Muscle Skeletal	14	0.48	1.9
GTEx	Nerve Tibial	17	0.39	1.9
GTEx	Ovary	7	0.77	2.1
GTEx	Pancreas	12	0.74	2.1
GTEx	Pituitary	7	0.63	2.1
GTEx	Prostate	8	0.96	2.1
GTEx	Skin Not Sun Exposed Suprapubic	14	0.57	2.0
GTEx	Skin Sun Exposed Lower leg	19	0.52	1.9
GTEx	Small Intestine Terminal Ileum	7	1.52	2.3
GTEx	Spleen	9	0.64	2.0
GTEx	Stomach	9	0.62	2.1
GTEx	Testis	22	0.70	1.9
GTEx	Thyroid	21	0.53	1.9
GTEx	Uterus	8	1.41	2.2
GTEx	Vagina	6	0.94	2.1
GTEx	Whole Blood	11	0.55	1.8
METSIM	Adipose	7	0.15	1.7
NTR	Blood	5	0.21	1.8
ROSMAP	Brain Pre-frontal Cortex	27	0.61	2.1
YFS	Blood	7	0.15	1.6
CommonMind	Brain Pre-frontal Cortex	17	0.32	1.9
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	7	0.42	1.9
The Cancer Genome Atlas	Breast Invasive Carcinoma	14	0.32	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	3	0.27	1.8
The Cancer Genome Atlas	Colon Adenocarcinoma	6	0.29	1.8
The Cancer Genome Atlas	Esophageal Carcinoma	5	0.73	2.0
The Cancer Genome Atlas	Glioblastoma Multiforme	4	0.39	2.0
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	10	0.37	1.9
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	13	0.32	1.8
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	4	0.20	1.9
The Cancer Genome Atlas	Brain Lower Grade Glioma	12	0.28	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	2	0.18	1.8
The Cancer Genome Atlas	Lung Adenocarcinoma	12	0.41	1.9
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	10	0.40	1.8
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	6	0.38	1.9
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	6	0.36	1.9
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	8	0.60	1.9
The Cancer Genome Atlas	Prostate Adenocarcinoma	10	0.22	1.7
The Cancer Genome Atlas	Rectum Adenocarcinoma	3	0.43	2.0
The Cancer Genome Atlas	Soft Tissue Sarcoma	5	0.47	1.8
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.19	1.7
The Cancer Genome Atlas	Stomach Adenocarcinoma	5	0.30	1.8
The Cancer Genome Atlas	Testicular Germ Cell Tumors	2	0.16	1.9
The Cancer Genome Atlas	Thyroid Carcinoma	12	0.23	1.7
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	1	0.20	1.7